Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Erweiterte Suche bearbeiten
Filter bei nächster Suche beibehalten
publishDate:"[2019 TO 2021]"
topic_facet:"Research Support, Non-U.S. Gov't"
topic_facet:"COVID-19 Vaccines"
journalStr:"Lancet (London, England)"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=publishDate%3A%22%5B2019+TO+2021%5D%22&filter%5B%5D=topic_facet%3A%22Research+Support%2C+Non-U.S.+Gov%27t%22&filter%5B%5D=journalStr%3A%22Lancet+%28London%2C+England%29%22&filter%5B%5D=topic_facet%3A%22COVID-19+Vaccines%22&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%22novel+coronavirus%22+OR+Covid+OR+%22Sars-CoV%22+OR+%22CoV-2%22+OR+ncov&type0%5B%5D=AllFields&op0%5B%5D=OR
/vufind/Search/Results?filter%5B%5D=publishDate%3A%22%5B2019+TO+2021%5D%22&filter%5B%5D=topic_facet%3A%22Research+Support%2C+Non-U.S.+Gov%27t%22&filter%5B%5D=journalStr%3A%22Lancet+%28London%2C+England%29%22&filter%5B%5D=topic_facet%3A%22COVID-19+Vaccines%22&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%22novel+coronavirus%22+OR+Covid+OR+%22Sars-CoV%22+OR+%22CoV-2%22+OR+ncov&type0%5B%5D=AllFields&op0%5B%5D=OR
Search /vufind/Search2/Results?filter%5B%5D=publishDate%3A%22%5B2019+TO+2021%5D%22&filter%5B%5D=topic_facet%3A%22Research+Support%2C+Non-U.S.+Gov%27t%22&filter%5B%5D=journalStr%3A%22Lancet+%28London%2C+England%29%22&filter%5B%5D=topic_facet%3A%22COVID-19+Vaccines%22&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%22novel+coronavirus%22+OR+Covid+OR+%22Sars-CoV%22+OR+%22CoV-2%22+OR+ncov&type0%5B%5D=AllFields&op0%5B%5D=OR
PubPharm (54)
1
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002) : a single-blind, randomised, controlled, phase 2/3 trial
enthalten in:
Lancet (London, England)
| 2021
von
Ramasamy, M.
|
Minassian, A.
|
Ewer, K.
| +162
ErratumIn: Lancet. 2021 Dec 19;396(10267):1978. - PMID 33341142
Wird geladen...
2
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) : interim results of a randomised, double-blind, controlled, phase 3 trial
enthalten in:
Lancet (London, England)
| 2021
von
Ella, R.
|
Reddy, S.
|
Blackwelder, W.
| +106
CommentIn: Lancet. 2021 Dec 11;398(10317):2134-2135. - PMID 34774194
Wird geladen...
3
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA : a retrospective cohort study
enthalten in:
Lancet (London, England)
| 2021
von
Tartof, S.
|
Slezak, J.
|
Fischer, H.
| +12
CommentIn: Lancet. 2021 Oct 16;398(10309):1382-1383. - PMID 34656213
Wird geladen...
4
Considerations in boosting COVID-19 vaccine immune responses
enthalten in:
Lancet (London, England)
| 2021
von
Krause, P.
|
Fleming, T.
|
Peto, R.
| +15
CommentIn: Lancet. 2022 Mar 26;399(10331):1224. - PMID 35339219
Wird geladen...
5
Global youth advocating for COVID-19 vaccines for all
enthalten in:
Lancet (London, England)
| 2021
von
Kaseje, N.
|
Walcott, D.
Wird geladen...
6
SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
enthalten in:
Lancet (London, England)
| 2021
von
Behrens, G.
|
Cossmann, A.
|
Stankov, M.
| +4
CommentOn: Lancet. 2021 Jul 10;398(10295):121-130. - PMID 34181880
Wird geladen...
7
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK : a substudy of two randomised controlled trials (COV001 and COV002)
enthalten in:
Lancet (London, England)
| 2021
von
Flaxman, A.
|
Marchevsky, N.
|
Jenkin, D.
| +135
CommentIn: Lancet. 2021 Sep 11;398(10304):933-935. - PMID 34480860
Wird geladen...
8
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV) : a single-blind, randomised, non-inferiority trial
enthalten in:
Lancet (London, England)
| 2021
von
Liu, X.
|
Shaw, R.
|
Stuart, A.
| +86
CommentIn: Lancet. 2021 Sep 4;398(10303):819-821. - PMID 34370969
Wird geladen...
9
Towards a European strategy to address the COVID-19 pandemic
enthalten in:
Lancet (London, England)
| 2021
von
Priesemann, V.
|
Balling, R.
|
Bauer, S.
| +25
Wird geladen...
10
COVID-19 vaccines for children in LMICs : another equity issue
enthalten in:
Lancet (London, England)
| 2021
von
Kampmann, B.
|
Okomo, U.
Wird geladen...
1
2
3
4
5
6
Nächster »
[6]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Erscheinungsjahr: 2019-2021
Filter aufheben
Thema: Research Support, Non-U.S. Gov't
Filter aufheben
Thema: COVID-19 Vaccines
Filter aufheben
Zeitschrift: Lancet (London, England)
Medienart
54
Aufsätze
54
E-Artikel
54
E-Ressourcen
Zeitschriftentitel
Lancet (London, England)
Thema
COVID-19 Vaccines
Research Support, Non-U.S. Gov't
37
Journal Article
17
Letter
12
B5S3K2V0G8
12
ChAdOx1 nCoV-19
11
Randomized Controlled Trial
10
BNT162 Vaccine
10
N38TVC63NU
10
Viral Vaccines
9
Antibodies, Viral
8
Antibodies, Neutralizing
7
Clinical Trial, Phase II
6
Multicenter Study
6
Spike Glycoprotein, Coronavirus
5
Comment
5
Immunoglobulin G
4
Clinical Trial, Phase III
3
Clinical Trial, Phase I
3
RNA, Messenger
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
2019-2021
43
2021
11
2020
Erscheinungsjahr(e)
Von:
Bis:
Sprache
54
Englisch
Haven't found what you're looking for?
Wird geladen...